Literature DB >> 11124674

Zone I retinopathy of prematurity.

X Katz1, A Kychenthal, P Dorta.   

Abstract

INTRODUCTION: Patients with zone I retinopathy of prematurity (ROP) have poor outcomes despite treatment. We analyze the clinical characteristics and treatment outcome of patients with zone I disease and compare them with patients with zone II disease.
METHODS: Preterm infants weighing less than 1500 g at birth were screened by the authors at age 4 to 6 weeks (group A). Group B was composed of referral patients that had been screened elsewhere. Findings were recorded according to the International Classification of Retinopathy of Prematurity. We classified all patients as either zone I, zone II, or zone III disease. If a retinopathy spanned 2 zones in one eye, it was classified in the most posterior zone as indicated by the International Classification of Retinopathy of Prematurity. Threshold was defined as in the Cryotherapy for Retinopathy of Prematurity study. Indirect diode-laser treatment was used to ablate the avascular retina. At the 3-month follow-up, outcome was judged according to Cryotherapy for Retinopathy of Prematurity criteria. Differences between eyes with zone I or zone II ROP were analyzed.
RESULTS: Group A was composed of 222 infants; 2 presented with zone I ROP. Of 63 patients comprising group B, 9 had zone I ROP: a total of 11 infants with zone I ROP, 22 eyes. At 3 months, 8 of 20 eyes with zone I ROP that were included in follow-up had an unfavorable outcome (40%). Mean birth weight and gestational age were similar in zone I and zone II cases, but mean gestational age at treatment was significantly different (35.2 weeks in zone I cases vs 37.2 weeks in zone II cases, P =.006). Unusual signs such as a demarcation vessel between vascular and avascular retina and excessive intraretinal neovascularization were observed in zone I eyes but not observed in eyes with zone II or zone III ROP. DISCUSSION: Zone I ROP appears to be different from zone II ROP. Earlier treatment age suggests either an early start, faster progression, or both. Special attention should be given to atypical morphology present in zone I ROP.

Entities:  

Mesh:

Year:  2000        PMID: 11124674     DOI: 10.1067/mpa.2000.107904

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  13 in total

1.  Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.

Authors:  Ramak Roohipoor; Hamed Ghasemi; Fariba Ghassemi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mehdi Nili-Ahmadabadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

2.  Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.

Authors:  Tapas Ranjan Padhi; Taraprasad Das; Prabhjot Kaur; Samir Sutar; Ashish Khalsa; Rohit Modi; Hasnat Ali; Lingaraj Pradhan; Subhadra Jalali
Journal:  Int Ophthalmol       Date:  2020-01-10       Impact factor: 2.031

3.  Idiopathic maculopathy in eyes with regressed retinopathy of prematurity.

Authors:  Kyoung Min Lee; Jeong Hun Kim; Young Suk Yu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-23       Impact factor: 3.117

4.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

5.  Low-dose ranibizumab administration in retinopathy of prematurity.

Authors:  Levent Tök; Lütfi Seyrek; Özlem Yalçın Tök
Journal:  Int Ophthalmol       Date:  2022-01-07       Impact factor: 2.031

6.  Development of 3D Printed Smartphone-Based Multi-Purpose Fundus Camera (MultiScope) for Retinopathy of Prematurity.

Authors:  Arivazhagan Pugalendhi; Rajesh Ranganathan
Journal:  Ann Biomed Eng       Date:  2021-11-12       Impact factor: 3.934

7.  Lens-sparing vitrectomy for stage 4 and stage 5 retinopathy of prematurity.

Authors:  Young Suk Yu; Seong-Joon Kim; So Young Kim; Ho Kyung Choung; Gyu Hyung Park; Jang Won Heo
Journal:  Korean J Ophthalmol       Date:  2006-06

8.  Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.

Authors:  Eun Jee Chung; Ji Hyun Kim; Hyun Seok Ahn; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-10       Impact factor: 3.117

9.  Macular Development in Aggressive Posterior Retinopathy of Prematurity.

Authors:  Hemang K Pandya; Lisa J Faia; Joshua Robinson; Kimberly A Drenser
Journal:  Biomed Res Int       Date:  2015-06-18       Impact factor: 3.411

10.  Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity.

Authors:  Odalis Arámbulo; Gabriel Dib; Juan Iturralde; Fahir Duran; Miguel Brito; João B Fortes Filho
Journal:  Clin Ophthalmol       Date:  2015-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.